Screener
Janux Therapeutics JANX Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
FAQ
- What is Janux Therapeutics's operating lease liabilities (total)?
- Janux Therapeutics (JANX) reported operating lease liabilities (total) of $20.99M in Q2 2026.
- How has Janux Therapeutics's operating lease liabilities (total) changed year-over-year?
- Janux Therapeutics's operating lease liabilities (total) decreased by 5.4% year-over-year, from $22.19M to $20.99M.
- What is the long-term trend for Janux Therapeutics's operating lease liabilities (total)?
- Over 4 years (2021 to 2025), Janux Therapeutics's operating lease liabilities (total) has grown at a 226.8% compound annual growth rate (CAGR), from $194K to $22.14M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.
Ask your AI about Janux Therapeutics's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude